Richard D. Carvajal, MD, the director of Experimental Therapeutics and director of Melanoma Service at the Columbia University Medical Center, discusses 2 therapies in clinical trials registering patients with melanoma.
Archive | Clinical Trials
Early Trials in Melanoma Show Better Response After 1 Year
Posted in Melanoma News, Health Professionals, Clinical Trials
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy vs placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial
Researchers conducted this randomised, double-blind, placebo-controlled, phase 2 trial to test the safety and effectiveness of adjuvant nivolumab plus ipilimumab or nivolumab monotherapy vs a placebo in patients with stage IV melanoma with no evidence of disease.
Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications
Idera’s tilsotolimod shows positive effect in mid-stage melanoma study
Idera Pharmaceuticals (IDRA -2.4%) announces final results from a Phase 1/2 clinical trial, ILLUMINATE-204, evaluating Toll-like receptor 9 (TLR9) agonist tilsotolimod, combined with Bristol-Myers Squibb’s (BMY -1.4%) Yervoy (ipilimumab), in metastatic melanoma patients.
Posted in Melanoma News, Health Professionals, Clinical Trials
On-off dosing of cancer drugs does not help melanoma patients
Drugs that home in on and block cell growth signals can dramatically shrink tumors, but all too often the cancer comes back. An attention-grabbing mouse study 7 years ago suggested these targeted drugs would work better at shrinking melanoma tumors if cancer patients got a break from their medicine every few weeks.
Posted in Melanoma News, Health Professionals, Clinical Trials
